ImmunoLogic, Bonus Episode: "Chemo Optional, Data Mandatory - A Year-End Recap"

We're excited to introduce another episode of the ImmunoLogic video podcast, hosted by Joseph Fraietta, PhD, an assistant professor of microbiology and the director of the Fraietta Lab at the University of Pennsylvania. Fraietta is joined by cohost Janna Minehart, MD, a clinical fellow in oncology (Master of Science Translational Research Program) at the University of Pennsylvania. Our hope is that this show will serve as a critical forum for clinicians, translational researchers, and biotechnology professionals to explore the evolving landscape of immunotherapy. We're seeking to bridge cutting-edge research with practical applications and delve into how immune-based therapies transition from innovative discoveries to transformative patient care solutions.

In this bonus episode recapping the year, the cohosts discussed highlights in immunotherapy from 2025—including some topics covered in previous episodes of the podcast, as well as some general notable happenings that occurred in the field during the year. The two touched on items including lymphoma therapy sequencing, next-generation sequencing, chimeric antigen receptor T-cell (CAR-T) therapy in solid tumors, the scale and cost of in vivo and allogeneic approaches to CAR-T, the evolving role of safety as a discipline, cancer vaccines, circulating tumor DNA (ctDNA) analysis, armored CARs, and more.

ImmunoLogic is tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility. This podcast is an essential resource for those driving the future of immunotherapy.

Interested in cohosting an episode or being a guest? Have feedback to share? If you'd like to get in touch to talk about the show, contact our editorial director, Matt Hoffman: [email protected].